<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02551991</url>
  </required_header>
  <id_info>
    <org_study_id>MM-398-07-02-03</org_study_id>
    <nct_id>NCT02551991</nct_id>
  </id_info>
  <brief_title>Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma</brief_title>
  <official_title>A Randomized, Open-label Phase 2 Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-Paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase 2 comparative study to assess the safety, tolerability, and
      preliminary efficacy of nal-IRI in combination with other anticancer therapies in patients
      not previously treated for metastatic pancreatic adenocarcinoma. This study will assess the
      following regimen:

      • nal-IRI + 5-fluorouracil (5-FU)/leucovorin (LV) + oxaliplatin

      The study will be conducted in two parts:

        1. Part 1a: a safety run-in as initial dose exploration

        2. Part 1b: dose expansion of the nal-IRI + 5FU/LV + oxaliplatin regimen
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">October 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety by reporting the adverse events and serious adverse events</measure>
    <time_frame>Up to 18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine dose limiting toxicities (DLT)</measure>
    <time_frame>Up to 28 Days post first treatment</time_frame>
    <description>For nal-IRI administered in combination with 5-FU/LV and oxaliplatin, the following adverse events will be considered as dose limiting toxicities (DLTs) if the following adverse events occur within 28 days of Cycle 1 or 14 days after Cycle 2 of treatment and are deemed related to the study treatment regimen:</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Cmax of total irinotecan, SN-38 and oxaliplatin</measure>
    <time_frame>Day 1 Predose, Day 1 at 1.5 hours (irinotecan and SN-38 only), Day 1 at 5.5 hours, Day 3, Day 8, Day 15, Day 30 Post last dose</time_frame>
    <description>Cmax (Observed maximal (peak) concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Cavg of total irinotecan, SN-38 and oxaliplatin</measure>
    <time_frame>Day 1 Predose, Day 1 at 1.5 hours (irinotecan and SN-38 only), Day 1 at 5.5 hours, Day 3, Day 8, Day 15, Day 30 Post last dose</time_frame>
    <description>Cavg (Average plasma concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Cmin of total irinotecan, SN-38 and oxaliplatin</measure>
    <time_frame>Day 1 Predose, Day 1 at 1.5 hours (irinotecan and SN-38 only), Day 1 at 5.5 hours, Day 3, Day 8, Day 15, Day 30 Post last dose</time_frame>
    <description>Cmin (Minimum plasma concentration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic AUCt of total irinotecan, SN-38 and oxaliplatin</measure>
    <time_frame>Day 1 Predose, Day 1 at 1.5 hours (irinotecan and SN-38 only), Day 1 at 5.5 hours, Day 3, Day 8, Day 15, Day 30 Post last dose</time_frame>
    <description>AUCt (Area under the plasma concentration time curve within a dosage interval (0 to last measurable concentration))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic CL of total irinotecan, SN-38 and oxaliplatin</measure>
    <time_frame>Day 1 Predose, Day 1 at 1.5 hours (irinotecan and SN-38 only), Day 1 at 5.5 hours, Day 3, Day 8, Day 15, Day 30 Post last dose</time_frame>
    <description>CL (apparent total body clearance of the drug from plasma after administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Vd of total irinotecan, SN-38 and oxaliplatin</measure>
    <time_frame>Day 1 Predose, Day 1 at 1.5 hours (irinotecan and SN-38 only), Day 1 at 5.5 hours, Day 3, Day 8, Day 15, Day 30 Post last dose</time_frame>
    <description>Vd (apparent volume distribution after administration)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 16 weeks post first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 16 weeks post first treatment</time_frame>
    <description>Duration from the date of enrolment/randomization to the time of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>up to 16 weeks post first treatment</time_frame>
    <description>Proportion of patients with Best overall response (BOR) characterized as either a Complete or Partial Response (CR or PR) relative to the total number of evaluable patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>up to 16 weeks post first treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and adverse event profile</measure>
    <time_frame>up to 18 months</time_frame>
    <description>The incidence of adverse events will be summarized by type of adverse event and severity. All patients who have received at least one dose of irinotecan liposome injection will be included in the safety analysis according to the National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>nal-IRI + 5-FU/LV + oxaliplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nal-IRI</intervention_name>
    <arm_group_label>nal-IRI + 5-FU/LV + oxaliplatin</arm_group_label>
    <other_name>MM-398</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 fluorouracil</intervention_name>
    <arm_group_label>nal-IRI + 5-FU/LV + oxaliplatin</arm_group_label>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>nal-IRI + 5-FU/LV + oxaliplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>nal-IRI + 5-FU/LV + oxaliplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the pancreas that has not
             been previously treated in the metastatic setting

          -  Unresectable, locally advanced or metastatic disease; diagnosed within 6 weeks prior
             to screening

          -  At least one tumor lesion measurable by CT or MRI scan (according to RECIST v1.1)

          -  ECOG performance status of 0 or 1 at screening and within 72 hours prior to first dose
             if first dose occurs more than 72 hours post-screening

          -  Adequate hematological, hepatic, renal and cardiac function

          -  Recovered from the effects of any prior surgery or radiotherapy

          -  Patient has a Karnofsky performance status (KPS) ≥ 70 at Screening, and within 72
             hours prior to date of first dose if first dose occurs more than 72 hours after
             screening (Part 1B only)

        Exclusion Criteria:

          -  Prior treatment of pancreatic cancer in the metastatic setting (or locally advanced
             setting) with surgery (placement of stent is allowed), radiotherapy, chemotherapy or
             investigational therapy

          -  Prior treatment of pancreatic cancer with chemotherapy in adjuvant setting, except
             those where at least 12 months have elapsed since completion of the last dose and no
             persistent treatment-related toxicities present

          -  Uncontrolled Central Nervous System (CNS) metastases

          -  Clinically significant gastrointestinal disorder

          -  History of any second malignancy in the last 3 years. Patients with prior history of
             in-situ cancer or basal or squamous cell skin cancer are eligible

          -  Presence of any contraindications for nal-IRI, irinotecan, 5-FU, leucovorin,
             oxaliplatin

          -  Use of strong CYP3A4 or inducers or presence of any other contra indications for
             irinotecan

          -  Pregnant or breast feeding

          -  Neuroendocrine or acinar pancreatic carcinoma

          -  Serum albumin &lt; 3 g/dL at screening visit and within 72 hours prior to first dose if
             first dose occurs more than 72 hours post screening

          -  Patients with symptoms and signs of clinically unacceptable deterioration of primary
             disease at time of screening

          -  Previous treatment with irinotecan-based, nab-paclitaxel-based or gemcitabine-based
             resulting in disease progression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ipsen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama - Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Avondale</city>
        <state>Arizona</state>
        <zip>85392</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles (UCLA) Medical Center - Santa Monica Cancer Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado (CU) Cancer Center - Anschutz Cancer Pavilion</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Cancer Center - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US Oncology - Comprehensive Cancer Centers of Nevada (CCCN)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center - Teaneck</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Health Sciences Center (OUHSC) Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gettysburg Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Group of the Carolinas - Spartanburg Regional Health Services</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Cancer Center and Institute of Academic Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Consultants - Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joe Arrington Cancer Research and Treatment Center - Lubbock</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John of God Health Care - Subiaco</name>
      <address>
        <city>Subiaco</city>
        <state>Western Australia</state>
        <zip>6008</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Elche - Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada - Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramon y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Madrid Sanchinarro Centro Integral Oncologico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>September 10, 2015</study_first_submitted>
  <study_first_submitted_qc>September 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2015</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>MM-398</keyword>
  <keyword>Metastatic pancreatic cancer</keyword>
  <keyword>First line pancreatic cancer treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

